Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers

Jennifer A. Sandberg, Vann P. Parker, Karin S. Blanchard, David Sweedler, James A. Powell, Arlee Kachensky, Laurent Bellon, Nassim Usman, Thomas H. Rossing, Ernest C. Borden,

The Journal of Clinical Pharmacology · 2000 · 44 citations · 22 references

Concepts

Abstract

The pharmacokinetics and tolerability of a chemically stabilized synthetic ribozyme (ANGIOZYME ™ ) targeting the Flt‐1 VEGF receptor mRNA were evaluated in healthy volunteers. In a placebo‐controlled, single‐dose escalation study, ribozyme was administered as a 4‐hour IV infusion of 10 or 30 mg/m 2 or as a SC bolus of 20 mg/m 2 . Peak ribozyme plasma concentrations of 1.5 and 3.8 μg/mL were observed after the 10 and 30 mg/m 2 IV infusions, respectively. When normalized to dose, AUC values as well as peak concentrations increased proportionally as the dose was increased from 10 to 30 mg/m 2 . Peak concentrations of 0.9 μg/mL were observed approximately 3.25 hours after a 20 mg/m 2 SC bolus of ribozyme. The dose‐normalized AUCs obtained after SC dosing were compared to the mean dose‐normalized AUC after IV dosing to estimate an absolute SC bioavailability (f) of approximately 69%. An average elimination half‐life of 28 to 40 minutes was observed after IV administration, which increased to 209 minutes after SC administration. Only 4 of 12 reported adverse events were possibly related to administration of ribozyme (headache and somnolence). Thus, ribozyme administration was well tolerated after a single 4‐hour IV infusion of up to 30 mg/m 2 or a single SC bolus of 20 mg/m 2 .

References

22